Profound Medical is commercializing a novel technology, TULSA-PRO®, which combines real-time MRI with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects.
TULSA-PRO® is a promising modality for localized prostate cancer and BPH, as it enables incision-free and targeted ablation of prostate tissue. The millimetre precision, the ability to personalize the treatment to the patient’s anatomy & pathology, and the promise of providing a safe minimally invasive solution with the potential to reduce side-effects, are key advantages of this technology.
TULSA-PRO® is CE marked and Profound Medical is currently conducting a pilot commercial launch of the technology in key European and other CE mark jurisdictions. The Company is also sponsoring a multicenter, prospective FDA-registered clinical trial, TACT, which, if successful, is expected to support its application to the FDA for approval to market TULSA-PRO® in the United States.